2025
SJR Q3
JCR Q3 · 1,8
OA
559 matched articles
SCIE
Journal detail
Journal of International Medical Research
- Publisher
- SAGE Publications Ltd
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
0300060514732300
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,481
- Quartile Q3
- H-Index 79
- Cites/doc 1,78
- Docs (3y) 1.515
- Cites (3y) 2.693
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 1,8
- 5Y JIF 1,8
- JCI 0,34
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Biochemistry Q3
- Biochemistry (medical) Q3
- Cell Biology Q4
- Medicine (miscellaneous) Q3
Areas
- Biochemistry, Genetics and Molecular Biology
- Medicine
WoS categories
- Medicine, Research & Experimental | Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q3 | 0,481 | 1,8 | 1,8 | 0,34 | Q4 | 79 |
| 2024 | Q3 | Q3 | 0,474 | 1,5 | 1,7 | 0,34 | Q4 | 74 |
| 2023 | Q3 | Q4 | 0,445 | 1,4 | 1,8 | 0,34 | Q4 | 74 |
| 2022 | Q3 | Q4 | 0,393 | 1,6 | 1,9 | 0,33 | Q4 | 74 |
| 2021 | Q3 | Q4 | 0,366 | 1,6 | 1,8 | 0,33 | Q4 | 74 |
| 2020 | Q3 | Q4 | 0,421 | 1,7 | 1,8 | 0,43 | Q3 | 74 |
| 2019 | Q3 | Q4 | 0,43 | 1,3 | 1,4 | 0,46 | Q3 | 74 |
| 2018 | — | Q4 | — | 1,4 | 1,5 | 0,48 | Q3 | — |
| 2017 | Q2 | Q4 | 0,516 | 1 | 1,4 | 0,45 | Q3 | 74 |
| 2016 | Q2 | Q4 | 0,608 | 1,3 | 1,5 | — | — | 74 |
| 2015 | Q2 | Q3 | 0,604 | 1,4 | 1,5 | — | — | 74 |
| 2014 | Q2 | Q3 | 0,617 | 1,4 | 1,4 | — | — | 74 |
| 2013 | Q2 | Q4 | 0,477 | 1,1 | 1,2 | — | — | 74 |
| 2012 | Q2 | Q4 | 0,424 | 1 | 1,1 | — | — | 74 |
| 2011 | Q2 | Q4 | 0,377 | 0,9 | 1 | — | — | 74 |
| 2010 | Q2 | Q4 | 0,411 | 1,1 | 1,1 | — | — | 74 |
| 2009 | — | Q4 | — | 0,9 | 1 | — | — | — |
| 2008 | — | Q4 | — | 0,8 | 0,9 | — | — | — |
| 2007 | — | Q4 | — | 0,8 | 0,8 | — | — | — |
| 2006 | — | Q4 | — | 0,7 | — | — | — | — |
| 2005 | — | Q4 | — | 0,7 | — | — | — | — |
| 2004 | — | Q4 | — | 0,5 | — | — | — | — |
| 2003 | — | Q4 | — | 0,6 | — | — | — | — |
| 2002 | — | Q4 | — | 0,8 | — | — | — | — |
| 2001 | — | Q4 | — | 0,7 | — | — | — | — |
| 2000 | — | Q4 | — | 0,6 | — | — | — | — |
| 1999 | — | Q3 | — | 0,5 | — | — | — | — |
| 1998 | — | Q4 | — | 0,4 | — | — | — | — |
| 1997 | — | Q4 | — | 0,5 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q4 | 136/191 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q4 | 258/356 |
| 2024 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | Q4 | 146/195 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 267/352 |
| 2023 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q4 | 144/189 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 275/354 |
| 2022 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q4 | 116/136 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 242/278 |
| 2021 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q4 | 123/139 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 249/279 |
| 2020 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 121/140 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 240/276 |
| 2019 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 121/139 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 241/271 |
| 2018 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 112/136 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 229/267 |
| 2017 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | Q3 | 116/133 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 231/261 |
| 2016 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 98/128 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 208/257 |
| 2015 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 91/124 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 197/255 |
| 2014 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 89/123 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 186/255 |
| 2013 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 97/124 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 203/256 |
| 2012 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 96/121 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 209/261 |
| 2011 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 89/112 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 212/261 |
| 2010 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 81/106 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 199/252 |
| 2009 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 78/93 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 193/237 |
| 2008 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 75/83 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 189/219 |
| 2007 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 69/81 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 181/205 |
| 2006 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 66/76 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 179/199 |
| 2005 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 63/72 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 174/193 |
| 2004 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 63/71 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 171/187 |
| 2003 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 61/72 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 159/185 |
| 2002 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 59/74 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 145/188 |
| 2001 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 58/75 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 148/186 |
| 2000 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 56/74 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 147/181 |
| 1999 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q3 | — | 56/76 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 145/175 |
| 1998 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 59/72 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 157/178 |
| 1997 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q4 | — | 49/61 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 139/157 |